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ABSTRACT
Transcatheter pulmonary valve replacement
(tPVR) has evolved into a viable alternative to
surgical conduit or bioprosthetic valve
replacement. This procedure has paved the
way for a more advanced approach to
congenital and structural interventional
cardiology. Although many successes have
been noted, there are still a number of
challenges with this procedure, including large
delivery systems, the need for a conduit or a
bioprosthetic valve as a landing zone for the
valve, optimal timing of the procedure to
prevent right ventricular failure, arrhythmias,
and possible death. Research is ongoing to
broaden the use of this technology when
treating patients with dilated right ventricular
outflow tracts, and early experience with a self-
expanding valve model has been reported.
Affordability is an important factor that must
be considered especially in developing nations.
The aim of this review is to emphasize the
advancement of tPVR, the benefits and
challenges of valve implantation, the current
state, and the future innovations associated
with this approach.
Keywords: Cardiology; Pulmonic
regurgitation; Right ventricular failure;
Transcatheter pulmonary valve replacement
INTRODUCTION
Implantation of a right ventricle (RV) to
pulmonary artery conduit has been vital in
treating patients with right ventricular outflow
tract (RVOT) obstruction with or without
pulmonary regurgitation [1, 2]. Utilizing these
conduits has provided positive results in the
treatment of uncommon forms of congenital
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heart disease (CHD), such as truncus arteriosus,
which were previously considered to be
untreatable [3]. Surgical correction utilizing
conduits in early life may also be required in
patients with pulmonary atresia with
ventricular septal defect or transposition of the
great arteries with a ventricular septal defect
and pulmonic stenosis.
Unfortunately, due to calcification or
scar formation leading to valve dysfunction,
conduits have limited durability, and
progressive conduit dysfunction may lead to
pulmonic regurgitation and/or stenosis [4, 5]. It
is estimated that conduit replacement surgery is
necessary anywhere between 10–15 years after
implantation [6]. More recent data categorize the
freedom from reintervention depending on the
age of the patient. Batlivala et al. [7] reported
freedom from RVOT reintervention to be
90% ± 3% at 5 years, 67% ± 5% at 10 years, and
47% ± 8% at 15 years, respectively.
In an effort to avoid reoperation, balloon
dilatation and stent placement has been
reported as a palliative treatment option for
conduit obstruction [8, 9], although these
procedures may result in free pulmonic
regurgitation (PR). Free PR progressively leads
to RV dilation that subsequently increases the
risk of ventricular arrhythmias, RV dysfunction,
and ultimately cardiac death [8, 9].
Transcatheter pulmonary valve replacement
(tPVR) has advanced into a feasible, less invasive
alternative to surgical conduit replacement.
Although data evaluating and comparing the
function and durability of tPVR with surgical
implants are lacking, short-to-medium term
outcomes for tPVR are very promising with
low morbidity and low valve failure rates
[7, 10]. The focus of this review is to detail the
progress and innovations of tPVR, and to
display future advancements that accompany
this technology.
HISTORY
In 2000, Bonhoeffer et al. [11] introduced and
reported the concept of tPVR mounted on a
balloon expandable stent in an ovine model. In
his first report, the native biological valves were
collected from fresh bovine jugular veins and
then trimmed to reduce the size of the delivery
system, at the same time maintaining safe
attachment of the tissue to the platinum
iridium stent. The stent was then expanded to
a radial diameter of 18 mm, and the length of
jugular vein was sutured to the interior of the
stent, spanning the entire axial length of
the stent. Device insertion was attempted via the
internal jugular approach in 11 lambs. Seven
out of 11 devices were successfully implanted;
five of the seven valves had the desired location
for valve implantation. The stent-valves were
explanted 2 months after implantation. Four of
the valves were mobile and competent with
slight stenosis secondary to visible calcification
in the fifth one. Although the overall success
rate was low at about 36%, these attempts
provided the platform for human studies [11].
Soon after, the same group reported the first
human transcatheter implantation in the
pulmonary position [12]. The valve was
implanted in a 12-year-old male patient with
pulmonary atresia and ventricular septal defect,
who had significant stenosis and insufficiency of
his 18 mm Carpentier-Edwards valve conduit
that was placed at age 4 years from the RV to
the pulmonary artery. The bovine jugular valve
was placed via the transfemoral approach and
successfully implanted into the degenerated
valve of the conduit. The pre-existing
pulmonary insufficiency was almost eliminated
with subsequent reduction in right ventricular
dimensions.
Two years later, Bonhoeffer et al. [13]
published further clinical experience in eight
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patients. All patients had successful implantation
of the valve in the desired position, and all had
significant improvement in their pulmonary
insufficiency. Valvar competence was achieved
in six patients, whereas relief of conduit
obstruction was partial in three patients and this
persisted at follow-up. Stent fractures were
reported in two patients [13].
CURRENT LITERATURE
After these initial successful attempts, efforts
focused on assessing the effectiveness and safety
of these valves as well as their longevity.
Bonhoeffer’s valve design was eventually
acquired by Medtronic and renamed the
Melody Valve (Medtronic Inc., Minneapolis,
MN, USA) and implantation was evaluated in
further clinical reports [13]. The conclusions
from these reports were that (a) the procedure is
safe, (b) the procedure is effective in eliminating
PR and reducing the indexed right ventricular
volumes, and (c) there is an improvement in the
New York Heart Association (NYHA) functional
class during a mean follow-up of 10 months
[14]. Freedom from surgical explantation was
83% at 12 months follow up with no mortality
reported [14]. Following further clinical
experience of tPVR using the Melody valve,
Lurz et al. [15] reported the freedom from
transcatheter reintervention as follows: 95%,
87%, 73%, and 73% at 10, 30, 50, and
70 months, respectively. It was also noted that
patients with a residual gradient [25 mmHg
were associated with a higher risk of
reintervention. Recently, a multicenter US
clinical trial showed freedom from Melody
valve dysfunction or reintervention was almost
95.4% at 1-year follow-up with a high rate of
procedural success (124/136), and improvement
in NYHA functional class [16].
The Edwards SAPIEN transcatheter heart valve
(THV; Edwards Life sciences LLC, Irvine, CA,
USA) was initially introduced as a transcatheter
alternative to surgical aortic valve replacement
in elderly patients with severe aortic stenosis
[17]. An initial report outlined successful
deployment in the pulmonary position in 2006
[18]. A subsequent clinical trial demonstrated
effective reduction in RVOT gradients, improved
clinical symptoms, and sustained pulmonary




There are currently two valves available
commercially, as shown in Fig. 1 and described
in Table 1. The Melody valve was approved by
the US Food and Drug Administration (FDA)
in January, 2010 for percutaneous valve
replacement under the Humanitarian Device
Exemption (HDE) program [20]. The Melody
valve is made from a bovine jugular vein valve
that is sewn into a platinum iridium stent
and preserved in a proprietary sterilant of
glutaraldehyde and alcohol [9, 10]. The Melody
valve comes in one size (18 mm diameter;
length, 28 mm) that is crimped to 6 mm and
re-expanded up to 22 mm. Its leaflets are very
compliant and flexible.
The Medtronic Ensemble delivery system
(Medronic Inc., Minneapolis, MN, USA),
comprises a delivery sheath with a balloon in
balloon (BiB) catheter (NuMED Inc., Hopkinton,
NY, USA) onto which the valve is front-loaded
and crimped. The polytetrafluoroethylene (PTFE)
sheath, which covers the valve during delivery is
withdrawn just prior to deployment. Three sizes
of the outer balloon are available: 18, 20, and
22 mm.
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The SAPIEN THV, approved for inoperable
patients with severe aortic stenosis [21] (not FDA
approved for the pulmonic position), is also a
bovine valve but produced from three equal-
sized bovine pericardial leaflets that are hand-
sewn to a stainless steel balloon-expandable
stent as shown in Fig. 2 and described in
Table 1. There is a fabric cuff covering the
lower portion of the stent’s frame (ventricular
side), which enables a seal with the calcified
conduit, may prevent paravalvular leak, and
limits stent expansion. The leaflet materials
were designed to reduce leaflet stress and
maximize coaptation. The valve is preserved
in low concentration solutions of buffered
glutaraldehyde, and is processed with the
Edwards ThermafixTM (Edwards Life Sciences,
Irvine, CA, USA) anticalcification pretreatment
that is also utilized in the Carpentier-Edwards
PERIMOUNT MagnaTM (Edwards Lifesciences),
surgical valve. This process involves heat
treatment of the tissue in glutaraldehyde and
uses ethanol and polysorbate-80.
The valve is available in two sizes: 23 mm with
a stent height of 14.3 mm and 26 mm with a stent
height of 16 mm [22]. The valve is mounted on a
custom-made 30-mm long balloon. The Retroflex
3 delivery system (Edwards Lifesciences) consists
of a balloon catheter and a deflectable guiding
catheter, and requires a 22 F (for the 23 mm valve)
and a 24 F (for the 26 mm valve) hydrophilic
35-cm long sheaths. A specialized Edwards
Crimper is used to symmetrically crimp the
valve onto the balloon. The Placement of
AoRTic traNscathetER valves (PARTNER II) trial
is currently evaluating the next generation of the
Fig. 1 The Medtronic Melody pulmonic valve; long axis (left) and short axis views (right)
Table 1 Comparison of Melody and the SAPIENTM valves
Characteristic Melody valve SAPIENTM valve
Stent material Iridium 10%, platinum 90% Stainless steel
Valve material Bovine jugular vein Bovine pericardium treated with ThermaﬁxTM
Available diameter (mm) 18–22 23 or 26
Stent height (mm) 34 14.5 or 16
Delivery sheath size (F) 22 22 or 24
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SAPIENTM THV, the SAPIEN XTTM in the aortic
position [23]. The stent material has changed
from stainless steel to a cobalt chromium alloy,
which allows a smaller delivery profile and sheath
size. Currently, the valve is available in Europe,
and is also available in a diameter of 29 mm, with
a stent height of 19.1 mm. The delivery system,
Novoflex catheter (Edwards Lifesciences) is
unique because it decreases the required sheath
size secondary to its capability to load the valve
onto the balloon inside the body. There are no
available data for this valve in the pulmonary
position. To the authors’ knowledge, this valve
was implanted in only one patient with a
good result (personal communication, Edwards
Lifesciences).
Each valve has its own advantages; although
the SAPIEN THVs are available in larger sizes and
shorter heights, which may be appropriate for
larger conduits and challenging anatomy, it has a
larger delivery system than the Melody valve,
which may render it more difficult to deliver.
Interestingly, the SAPIENTM THV system does not
use a covering sheath; therefore, once it exits its
delivery sheath (35-cm long) it may be difficult to
retract inside the sheath. Conversely, the Melody
system is less bulky, and its retractable sheath
protects the valve until it is deployed; however, its
limitation to 22 mm makes it less valuable
for those with larger conduits. Deployment of
the Melody valve on a 24 mm balloon has
been performed successfully with minimal
regurgitation (personal communication, John P.
Cheatham, MD).
In a recent study conducted in the authors’
center, both valves demonstrated comparable
function at short-term follow-up with a greater
initial residual RVOT gradient in the SAPIEN
cohort; however, this was thought to be
secondary to a less aggressive prestenting
strategy with the Edwards cohort [24].
INDICATIONS
The adverse impact of RV dilatation and
dysfunction is well studied in patients with
tetralogy of Fallot. Exercise intolerance,
heart failure, arrhythmias, right ventricular
dysfunction, and death, are late complications
after repair. The pressure gradient across
previously placed surgical conduits increases
the pressure and volume load of the RV and
may eventually lead to these complications.
Numerous studies have attempted to stratify the
Fig. 2 The Edwards Lifesciences SAPIENTM valve; long axis (left) and short axis views (right)
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risks; QRS duration of[180 ms has been shown
to be an independent predictor of sudden death
[9]. In 2007, Oosterhof et al. showed early
intervention is beneficial in patients with
preoperative QRS [150 ms [25]. Cardiac
magnetic resonance (CMR) imaging has been
used to determine the timing of intervention
based on RV ejection fraction, volume, and
pulmonary regurgitation. Currently, surgical
intervention is indicated with indexed right
ventricular end-diastolic volumes (RVEDV)
[150 mL/m2 based on recently published data,
as studies have suggested an indexed RVEDV
that exceeds 150 mL/m2 may lead to irreversible
RV dilation despite successful valve replacement
[26].
The 2010 American Heart Association
statement on the Indications for Cardiac
Catheterization and Intervention in Pediatric
Cardiac Disease was expanded to include a class
2a indication for tPVR [27]; the recommendation
was: ‘It is reasonable to consider percutaneous
pulmonary valve replacement in a patient
with an RV-to-pulmonary artery conduit with
associated moderate to severe pulmonary
regurgitation or stenosis provided the patient
meets inclusion/exclusion criteria for the
available valve (level of evidence: B).’ These
recommendations are somewhat vague, and
therefore, to date, indications have mirrored
those for published clinical trials [27]. The
inclusion and exclusion criteria for both the
Melody and SAPIEN valve trials are summarized
in Table 2.
PROCEDURAL TECHNIQUE
After a complete history, physical examination,
and reviewing the preprocedural laboratory
and imaging investigations, including
echocardiography and computed tomography
(CT)/CMR, the patient is taken to the
catheterization laboratory. The procedure is
performed under general endotracheal
anesthesia. Access is usually obtained via the
femoral vein (preferred site for valve delivery);
however, the procedure may also be performed
via the internal jugular vein. A 7 F and a 5 F
sheath are used for venous and arterial access,
respectively. After obtaining access, the patient
is given intravenous heparin, to achieve an
activated clotting time (ACT) of [200 s,
preferably [250 s.
Standard right heart catheterization is
performed to assess the preprocedural
saturations, pressures, and the pressure gradient
across the dysfunctional conduit (Fig. 3a).
Angiography is then performed as follows:
straight lateral and frontal with 20 cranial.
Selective coronary angiography is performed
simultaneously with a noncompliant angioplasty
balloon in the RVOT conduit. Adequate
angiographic distance (at least 10 mm) from the
edge of the inflated balloon to the origin of the left
coronary artery must exist to place the valve safely
without compression of the coronary arteries
(Fig. 3b). Angiographic assessment of the RVOT
size, anatomy, and RV function is of paramount
importance to ensure appropriate valve delivery is
feasible (Fig. 3a–d).
It is important to measure the RVOT in two
dimensions (utilizing biplane fluoroscopy) to
ensure the RVOT is suitable for valve delivery.
In the COMPASSION trial, implantation of the
23 mm valve was recommended when the final
conduit (with a bare stent) diameter was
between 19–21 mm and the 26 mm valve was
best implanted when the final conduit diameter
was 21–23 mm.
Due to the short height of the Edwards valve
and to provide an adequate landing zone,
prestenting of the RVOT with a bare metal
stent prior to valve delivery is a must and
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prestenting has also become standard (to reduce
stent fracture) when implanting the Melody
valve (Fig. 3c).
The bare metal stent is usually deployed on a
BiB catheter (NuMED Inc; Fig. 3d, e) over a stiff
guide wire placed preferably in the left
pulmonary artery. Prior to valve insertion, the
valve stent is crimped symmetrically using a
specialized crimping device onto a 30 mm-long
presized balloon catheter. The valve is delivered
Fig. 3 SAPIENTM valve placement steps. a MPA
(homograft) angiography demonstrates severe pulmonic
regurgitation. b MPA balloon sizing with simultaneous
aortic root angiography; large arrow shows the balloon
inﬂation in the RVOT, small arrow demonstrates LCA with
an acceptable distance from the RVOT. c Bare-metal stent
placement in homograft with hand injection angiography to
delineate stent position. d Balloon stent deployment.
e Angiography poststent deployment demonstrating no
homograft stenosis with free PR. f Edward SAPIENTM valve
in the middle of stent. g Balloon deployment of the valve.
h Excellent valve position inside stent. i Final angiography in
MPA demonstrating no signiﬁcant PR. LCA left coronary
artery, MPA main pulmonary artery, PR pulmonic regur-
gitation, RVOT right ventricular outﬂow tracts
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across the prestented outflow tract over a very
stiff guide wire; Meier wire (Boston Scientific
Corporation, Natick, MA, USA), or Lunderquist
wire (Cook Medical, Bloomington, IN, USA).
Multiple angiograms are performed prior to
balloon inflation to ensure proper position of
the stent; this is usually not necessary if there is
a stent already in place (Fig. 3f–i).
Postprocedural imaging with angiography
and/or intracardiac echocardiography (ICE) is
performed to evaluate the site and function of
the implanted valve (Fig. 4). ICE enables
evaluation of the pressure gradient by Doppler
and the degree of valve regurgitation or
perivalvular leak.
Hemostasis is achieved after the procedure
with either Perclose sutures (Abbott Vascular,
Abbott Park, IL, USA) [19], which should have
been inserted prior to inserting the large sheath
(preclose), or simply by (Figure-of-Eight)
suturing technique [28].
Following the procedure, the patient is
admitted to the intensive care unit for close
observation overnight. Complete physical
Fig. 4 Intracardiac echocardiography (ICE) images.
a Two-dimensional ICE in systole demonstrating complete
opening of SAPIEN valve leaﬂets. b Color Doppler in
systole demonstrating no narrowing passing SAPIEN valve.
c Two-dimensional ICE in diastole demonstrates complete
valve closure. d Color Doppler in diastole demonstrates
trivial PR
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examination, electrocardiogram (ECG), chest
x-ray, and echocardiography are performed
prior to patient discharge. Aspirin 81 mg is
advised for at least 1 year.
Follow-up outpatient visits are recommended
at 1, 6, and 12 months, and yearly thereafter. A
chest radiograph is obtained at 6 months to
investigate the position of the valve/stent and
any potential stent fracture. Echocardiography
is routinely used to evaluate RV function,
regurgitation, and/or stenosis with each visit.
CT or CMR is also part of the follow-up protocol.
POTENTIAL COMPLICATIONS
Procedural complications may necessitate
conversion to surgery; these include valve
migration, homograft rupture, guide wire injury
toadistalbranch pulmonaryartery,damage to the
tricuspid valve, and arrhythmia. Initial reports
associated with these complications were
documented to be as high as 12% in early studies
[14]; however, recent studies have demonstrated a
reduction in major complications to 5–6% [7]. A
study published by Bonhoeffer’s group in 2008
reported that after their first 50 patients,
procedural complications decreased from 6.0%
to 2.9% [15].
A recent study demonstrated that 4.4% of the
US cohort possessed unsuitable anatomy for
valve implantation due to concerns regarding
potential coronary artery compression [7]. This
issue may be evident by using CT/magnetic
resonance angiography, which may indicate
the distance between the coronary artery and
conduit; however, this should not be relied upon
as stent implantation will distort the pre-existing
anatomy, and selective coronary angiography
with a noncompliant balloon inflated in the
RVOT should always be performed prior to
attempted stent/valve implantation.
Conduit rupture has also been reported [15].
Risk factors have yet to be fully elucidated.
Increasingly covered stents are being used with
aggressive prestenting of heavily calcified
conduits. In the event of conduit rupture, self-
expanding covered stents or, if available,
balloon expandable covered stents should be
used to create a seal and prevent further risk of
bleeding [29].
Device-related complications are usually
detected postprocedure. The ‘‘Hammock’’
effect—in which the valve does not oppose the
stent leading to stenosis—was detected in
patients undergoing early Melody valve
implantation and was associated with a high
incidence of in-stent stenosis [30]. This is
attributed to the malapposition of the valve to
the stent. The detection of this problem lead to
the modification of the design of the Melody
valve, in which additional sutures were
implanted at all strut intersections. Another
problem that can require reintervention is
stent fracture, which has been reported to be as
high as 43% without bare-metal stenting of the
RVOT [31]. Nordmeyer et al. [32] reported a 75%
freedom from Melody stent fracture (MSF) at
2 years in the native RVOT. In the multicenter
trial for Melody valve implantation [16], short
and medium-term follow-up data demonstrated
that the freedom from stent fracture was
83.7% ± 3.7% at 7.5 months and 77.8% ± 4.3%
at 14 months. Reduction in the rate of stent
fracture has been noted with prestenting of the
RVOT [33]. The risk factors for stent fracture
were not evaluated in this cohort. Stent fracture
has not been reported with the SAPIEN valve.
In December 2011, McElhinney et al. [34]
reported the multicenter trial for Melody valve
implantation. They assessed, in detail, the risk
factors for MSF, valve dysfunction, and
reintervention. The median follow up was
30 months. MSF was classified into three types
Page 10 of 14 Cardiol Ther (2012) 1:5
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according to Nordmeyer et al. [32]: type 1,
fracture of one or more strut without loss of
stent integrity; type 2, fracture with loss of stent
integrity; and type 3, fracture associated with
separation of fragments or embolization. Thirty-
nine out of 150 patients were diagnosed with
MSF; 33 patients were classified as type I.
Seventeen patients were diagnosed with a type
2 MSF; (11 patients progressed from type 1–2
and six were diagnosed as type 2). One patient
had a type III MSF with embolization to the RV
of a single strut segment.
Freedom from a diagnosis of MSF was 77% ±
4% at 14 months, 68% ± 5% at 27 months, and
60% ± 9% at 39 months, respectively. Freedom
from a diagnosis of type II MSF was 85% ± 4% at
27 months and 74% ± 11% at 39 months. The
authors also assessed the risk factors associated
with MSF [34]; severe conduit obstruction and
the position of the implanted valve behind the
sternum were associated with shorter freedom
from MSF.
Valve-in-valve tPVR has been performed to
treat the Hammock effect, stent fractures,
and residual stenosis. It has been noted
that repeat tPVR has resulted in freedom from
surgical reintervention [35]. In a multicenter
trial for valve-in-valve implantation for failed
bioprosthetic heart valves, six patients underwent
successful implantation of the Edward SAPIEN
valve in the pulmonary position; there was no
mortality within the 6 month follow-up period.
[36]. However, repeat tPVR is not suitable in all
instances. Although, where appropriate, this
approach should be considered an alternative to
surgery as using this management strategy
may indefinitely halt the need for surgical
reintervention.
Prestenting has primarily focused on
reduction of stent fracture and a recent report
with high patient proportion of prestenting
(95%) demonstrated stent fractures as low as 5%
[33]. Operators have adapted the prestenting
technique with covered stents—if these are
available—to prevent conduit rupture [35],
while others have advocated preparation of a
covered stent as a bail out in the case of conduit
disruption.
The size of the patient and of the RVOT have
limited the available 22 F delivery system for
both the Melody and SAPIEN valves to
transfemoral approaches in children over
20 kg. This will limit the extended application
of the currently available valves; however, the
internal jugular vein may be used in these
smaller patients. An alternative approach was
also reported for both valves with valve delivery
directly through the heart through a sheath
placed in the RV free wall [36, 37].
Endocarditis has been reported in 3.2% of
patients over a median follow-up of 5 months
following implantation of tPVR, [15]. The
culprit organisms were Staphylococcus aureus,
Streptococcus spp., and also Candida albicans in
one patient with compromised immunity [15].
American Heart Association (AHA) guidelines
recommendation stated: prophylaxis is




Description of transcatheter pulmonary valve
implantation in a dysfunctional RV- pulmonary
artery conduit over a decade ago is still
considered as an important step towards further
potential for this emerging field in interventional
cardiology. The rapid advancement of this
technique and valve design offers patients the
opportunity of less invasive intervention/
reintervention and may lead to less morbidity
and faster recovery. With an improvement in the
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inevitable learning curve, the rate of procedural
complications is dropping significantly [15].
Multicenter trials and development of protocols
may broaden the applicability of this technology
significantly.
Comparative data with the surgical
alternative requires further research. One of
the difficulties that interventionists are facing is
the size of the delivery system that renders tPVR
rather challenging for small children. Therefore,
miniaturization of the delivery system/valve
should be explored to benefit the thousands of
small children with dysfunctional homografts/
bioprostheses. To date, short and medium
follow-up data are encouraging [16].
In a recent animal study, Kiefer et al.
examined the effect of Edward SAPIEN valve
crimping on valve calcification and durability.
Their conclusion was precrimping of the valve
for less than 1 day will result in no significant
change in the structural integrity of valve tissue
compared to the group crimped for more than
1 day. The calcification grade was similar in
both groups when compared to a control group
[39]. In order to overcome the complications
that result from valve calcification and
degeneration, ongoing work is being carried
out to investigate tissue engineering techniques
to preserve valve function [40, 41]. Mid-term
follow-up for these tissue-engineered vascular
grafts have demonstrated the valves to be safe
and effective with excellent hemodynamics in
pediatric cardiovascular surgery [42]. Schmidt
et al. [43] recently demonstrated that heart
valve tissue engineering (HVTE) implantation
through the transcatheter approach is feasible
but requires technical and financial support.
More recently Weber et al. [44] demonstrated
successful implantation of bone marrow
mononuclear cell (BMMC) derived tissue-
engineered heart valve (TEHV) into the
pulmonary position. In an ovine model,
BMMC-derived TEHV can be implanted
successfully using a minimally invasive, one-
step, transapical approach in the aortic position
[45].
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